TY  - JOUR

T1  - Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

JO  - Drug Design, Development and Therapy

UR  - https://eprints.whiterose.ac.uk/id/eprint/107903

UR  - http://dx.doi.org/10.2147/DDDT.S84177

PY  - 2015/09/03

AU  - Wolin EM

AU  - Jarzab B

AU  - Eriksson B

AU  - Walter T

AU  - Toumpanakis C

AU  - Morse MA

AU  - Tomassetti P

AU  - Weber MM

AU  - Fogelman DR

AU  - Ramage J

AU  - Poon D et al

ED  - 

DO  - DOI: 10.2147/DDDT.S84177

PB  - Dove Medical Press

VL  - 9

SP  - 5075

EP  - 5086

Y2  - 2025/11/05

ER  -